Trial Profile
An Exploratory proof-of Mechanism Study to Assess the Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells and Additional Immune Subsets in Prostate Cancer Patients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 24 Mar 2020 Status changed to withdrawn prior to enrolment.
- 24 Mar 2020 Planned End Date changed from 31 Dec 2019 to 24 Mar 2020.
- 24 Mar 2020 Planned primary completion date changed from 31 Dec 2019 to 24 Mar 2020.